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A pneumonia of unknown source was first reported
to the World Health Organization Country Office
from Wuhan, China, on December 31, 2019. Analysis
of the samples obtained from the lower respiratory
tract confirmed a novel coronavirus, which is now
known as coronavirus disease 2019 (COVID-19). On
March 11, 2020, the World Health Organization stated
that COVID-19 was a pandemic disease with a mor-
tality rate of about 3.7%.1,2 Recently, several studies
have reported that a subgroup of patients with intense
COVID-19 could have suffered from a cytokine release
syndrome (CRS).2 CRS is a potentially life-threatening
toxicity with an initial increase of tumor necrosis
factor-α (TNF-α), followed by an increase in inter-
leukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, and interferon-
γ (IFN-γ ).3 A cytokine profile was detected in
COVID-19, including increased IL-2, IL-7, IFN-γ ,
granulocyte colony-stimulating factor, monocyte
chemoattractant protein 1, macrophage inflammatory
protein 1-α, and TNF-α.4 In addition, increased ferritin
and IL-6 were introduced as predictors of fatality in
COVID-19.5 All reported data could be considered
as proof, confirming the activation of inflammation
processes and the occurrence of CRS in critical patients
with COVID-19.
Colchicine is as an old drug, an alkaloid derived
from autumn crocus, which has been used to treat
several inflammatory diseases for many years. Several
mechanisms of action for the anti-inflammatory effects
of colchicine have been reported in the literature.6,7
The ability of colchicine to bind to free tubulin dimers,
which may result in the blockage of the following mi-
crotubule polymerization,8 is believed to be one of the
most famous mechanisms. This mechanism seems to
lead to the interruption of inflammatory cell activities
and cytokine release.9 Moreover, colchicine may con-
trol the white blood cell (WBC)-mediated inflammatory
activities, counting the inhibiting WBC production of
superoxides and release of numerous cytokines and
pyrogens.10 Therefore, it may generally target WBCs,
resulting in microtubule depolymerization, which in
turn inhibits motility, phagocytosis, and degranulation
of the WBCs. Furthermore, colchicine may suppress
IL-1β and IL-18 release by interacting with Nod-like
receptor protein 3 inflammasome protein complex.11
Colchicine is approved for the treatment of patients
with acute gout and familial Mediterranean fever as
well as other inflammatory conditions, including peri-
carditis and acute coronary syndrome (ACS), urarthri-
tis, and other disorders.12-14
Martínez et al13 studied the effect of colchicine on
local cardiac production of inflammatory cytokines
in patients with ACS. They concluded that the local
cardiac production of inflammatory cytokines contain-
ing IL-1β, IL-18, and IL-6 were elevated in patients
with ACS. It was also inferred that the treatment with
short-term colchicine could quickly and predominantly
decrease the levels of IL-1β, IL-18, and IL-6 cytokines.
Recently, Mehta et al2 recommended that immuno-
suppression could be useful in patients with severe
COVID-19 by hyperinflammation.
According to a recent hypothesis, production of the
inflammatory cytokines such as IL-1β and IL-6 is a key
downstream inflammatory mechanism in patients with
severe COVID-19. Therefore, colchicine, as a simple
and cheap drug with adequate safety profile, can be
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proposed as a potential candidate for alleviating the
inflammatory conditions. However, to the best of our
knowledge, only a phase 3, multicenter, randomized,
double-blind, placebo-controlled multicenter study has
been recently assigned to clinicaltrials.gov by Mon-
treal Heart Institute, to investigate the efficacy and
safety of colchicine in adult patients diagnosed with
COVID-19 with a minimum of 1 high-risk criterion
(NCT04322682). In addition, we have designed a study
to evaluate the efficacy and safety of a combina-
tion of colchicine and TNF-α inhibitors in patients
with severe COVID-19. This combination was selected
based on the mentioned potential therapeutic effects of
colchicine and TNF-α inhibitors due to possible effects
in modulation of severe acute respiratory syndrome
coronavirus infection.15
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